SA PRO
Free Account
Themes
Amgen Inc.AMGNNASDAQ
Loading
OverviewIntelligenceChartsNews

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
28 analysts·High coverage
50%
Rating Distribution
Strong Buy
00%
Buy
1450%
Hold
1139%
Sell
311%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 8% above analyst consensus — modest downside expected.

Bear Case
$185.00
-51%
Consensus
$347.00
-8%
Bull Case
$432.00
+15%
Price Range28 analysts
Low
Consensus
High
$185.00
$432.00
Current Target
Current Price
$377.00
Above Target
$30.00

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Feb 19, 2026Barclays
Amgen initiated with an Equal Weight at Barclays
Target:$185.00
-50.7%from $375.50
Feb 19, 2026Wells Fargo
Amgen price target raised to $375 from $325 at Wells Fargo
Target:$375.00
-1.2%from $379.73
Feb 18, 2026Piper Sandler
Amgen price target raised to $432 from $381 at Piper Sandler
Target:$432.00
+15.7%from $373.36
Feb 11, 2026Mizuho Securities
Amgen price target raised to $295 from $280 at Mizuho
Target:$295.00
-19.1%from $364.65
Feb 4, 2026RBC Capital
Amgen price target raised to $360 from $335 at RBC Capital
Target:$360.00
+0.8%from $357.29
Feb 4, 2026Morgan Stanley
Amgen price target raised to $309 from $304 at Morgan Stanley
Target:$309.00
-12.2%from $351.81
Jan 29, 2026Oppenheimer
Amgen price target raised to $400 from $380 at Oppenheimer
Target:$400.00
+16.4%from $343.57
Jan 26, 2026UBS
Amgen price target raised to $390 from $380 at UBS
Target:$390.00
+11.8%from $348.99
Jan 20, 2026Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
Target:$335.00
+1.4%from $330.44
Jan 6, 2026UBS
Amgen assumed at Buy from Neutral at UBS
Target:$380.00
+15.1%from $330.17
Dec 12, 2025Morgan Stanley
Amgen price target lowered to $304 from $329 at Morgan Stanley
Target:$304.00
-4.3%from $317.67
Dec 10, 2025HSBC
Amgen price target raised to $425 from $381 at HSBC
Target:$425.00
+35.4%from $313.85
Dec 3, 2025BMO Capital
Amgen price target raised to $372 from $335 at BMO Capital
Target:$372.00
+9.9%from $338.36
Nov 25, 2025Wells Fargo
Goldman Sachs Reiterates Buy Rating on Amgen (AMGN)
Target:$400.00
+19.7%from $334.30
Nov 24, 2025Truist Financial
Amgen assumed with a Hold at Truist
Target:$318.00
-5.4%from $336.19
Nov 14, 2025Piper Sandler
Amgen (AMGN) PT Raised to $381 at Piper Sandler
Target:$381.00
+14.6%from $332.43
Nov 6, 2025Cantor Fitzgerald
Amgen price target raised to $315 from $305 at Cantor Fitzgerald
Target:$315.00
-1.1%from $318.40
Nov 5, 2025Wells Fargo
Amgen price target raised to $300 from $280 at Wells Fargo
Target:$300.00
+1.1%from $296.70
Aug 25, 2025Piper Sandler
Amgen price target raised to $342 from $328 at Piper Sandler
Target:$342.00
+18.6%from $288.47
May 2, 2025UBS
Amgen price target lowered to $315 from $319 at UBS
Target:$315.00
+12.0%from $281.22
Apr 22, 2025Cantor Fitzgerald
Amgen assumed at Neutral from Overweight at Cantor Fitzgerald
Target:$305.00
+9.6%from $278.40
Mar 5, 2025Johnson Rice
Amgen price target raised to $294 from $275 at BofA
Target:$294.00
-7.1%from $316.57
Nov 12, 2024Jefferies
Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
Target:$380.00
+27.2%from $298.84
Nov 12, 2024Cantor Fitzgerald
Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data
Target:$405.00
+35.5%from $298.84
Oct 21, 2024Morgan Stanley
Morgan Stanley names Amgen 'catalyst-driven idea' into Phase 2 MariTide data
Target:$319.00
+0.7%from $316.74

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance